Practical Management of Early Stage HER2+ Breast Cancer

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment ArsenalПодробнее

Case 1: Approach to Early Stage, HER2+ Breast CancerПодробнее

Perioperative Treatment of Early Stage HER2+ Breast CancerПодробнее

#ESMO21 Expert Video Report on HER2-positive early breast cancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Scalp cooling & breast cancer treatment: What providers need to knowПодробнее

Overcoming resistance to trastuzumab deruxtecan in HER2-low cancersПодробнее

Treatment for Early Stage HER2+ Breast Cancer | Dana-Farber Cancer InstituteПодробнее

Early Stage Breast Cancer | 2022 OneOncology ConferenceПодробнее

Optimizing treatment in patients with early-stage HER2-positive breast cancerПодробнее

Key challenge associated with the management of HR+/HER2- breast cancerПодробнее

Overview of the management of HER2-low breast cancer patientsПодробнее

Practical Considerations in Managing Early HER2+ Breast CancerПодробнее

HER2+ Early-Stage Breast Cancer: Neoadjuvant StrategiesПодробнее

Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast ConferenceПодробнее

Guideline Updates for Extended Endocrine Therapy Decision-Making in HR+, Early-Stage Breast CancerПодробнее

Management of Early Breast CancerПодробнее

HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancerПодробнее

Adjuvant Strategies in Early-Stage HER2+ Breast CancerПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

Conceptualizing Guidelines to Manage Patients with HR–Positive, HER2-Negative Early Breast CancerПодробнее